Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Real-World Evidence of the Use of Carfilzomib Among Multiple Myeloma Patients with at Least One Prior Therapy across 10 European Countries and Israel

Evangelos Terpos, MDPhD, Borhane Slama, MD, Renato Zambello, Sorina Nicoleta Badelita, MD, Eirini Katodritou, MD, Jo Caers, MD PhD, Thomas Kühr, MD, Florence Suzan, MD, Abeera Mohammad, MSc, Sally Wetten, MSc, Xavier Leleu, MD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-134475

Published: 2020

Journal Articles

Real-World Evidence of the Use of Approved Carfilzomib Regimens in Patients Previously Exposed or Refractory to Lenalidomide: Updated Results from a Prospective Observational Study

Xavier Leleu, MD, Borhane Slama, MD, Renato Zambello, Sorina Nicoleta Badelita, MD, Eirini Katodritou, MD, Jo Caers, MD PhD, Thomas Kühr, MD, Florence Suzan, MD, Abeera Mohammad, MSc, Sally Wetten, MSc, Evangelos Terpos, MDPhD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-134476

Published: 2020

Journal Articles

Ixazomib, Thalidomide and Dexamethasone (IxaThalDex) in Relapsed/Refractory Multiple Myeloma (RRMM): An Interim Analysis of a Phase II Trial

Heinz Ludwig, MD, Eberhard Gunsilius, MD, Michael Fridrik, MD, Richard Greil, Andreas Petzer, MD, Thomas Kühr, Univ. Doz. Dr., Stefan Knop, MD, Martin Schreder, MD, Elisabeth Rauch, Mag., Wolfram Poenisch, MD, Niklas Zojer, MD

Blood (2016) 128 (22): 3335.

https://doi.org/10.1182/blood.V128.22.3335.3335

Published: 2016

Journal Articles

Treatment with Bendamustine-Bortezomib-Dexamethasone (BBD) in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated

Heinz Ludwig, Hedwig Kasparu, Richard Greil, MD, Clemens Leitgeb, Ercan Müldür, Elisabeth Rauch, Niklas Zojer, Eva Maria Autzinger, Werner Linkesch, Thomas Kuhr, Ludek Pour, MD, PhD, Zdenek Adam

Blood (2012) 120 (21): 943.

https://doi.org/10.1182/blood.V120.21.943.943

Published: 2012

Journal Articles

Significant Activity of Lenalidomide-Dexamethasone in Multiple Myeloma (MM) Patients with Light Chain Induced Acute Renal Failure (LC-ARF)

Heinz Ludwig, Elisabeth Rauch, Thomas Kuhr, Adalbert Weissman, Daniel Heintel, Niklas Zojer, Hedwig Kasparu, Richard Greil, MD, Zdenek Adam

Blood (2012) 120 (21): 4031.

https://doi.org/10.1182/blood.V120.21.4031.4031

Published: 2012

Journal Articles

BCR-ABL Positive Chronic Myeloid Leukaemia (CML) with Del 11q22 and JAK 2 V617F Positive Chronic Myelomonocytic Leukaemia (CMML) in One Patient – a Rare Coincidence

Sonja Burgstaller, MD, Gerald Webersinke, Dr, Beate Mayrbaeurl, MD, Thomas Kuhr, MD, MPH, Josef Thaler, MD

Blood (2011) 118 (21): 4891.

https://doi.org/10.1182/blood.V118.21.4891.4891

Published: 2011

NARROW

Real-World Evidence of the Use of Carfilzomib Among Multiple Myeloma Patients with at Least One Prior Therapy across 10 European Countries and Israel

Real-World Evidence of the Use of Approved Carfilzomib Regimens in Patients Previously Exposed or Refractory to Lenalidomide: Updated Results from a Prospective Observational Study

Ixazomib, Thalidomide and Dexamethasone (IxaThalDex) in Relapsed/Refractory Multiple Myeloma (RRMM): An Interim Analysis of a Phase II Trial

Treatment with Bendamustine-Bortezomib-Dexamethasone (BBD) in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated

Significant Activity of Lenalidomide-Dexamethasone in Multiple Myeloma (MM) Patients with Light Chain Induced Acute Renal Failure (LC-ARF)

BCR-ABL Positive Chronic Myeloid Leukaemia (CML) with Del 11q22 and JAK 2 V617F Positive Chronic Myelomonocytic Leukaemia (CMML) in One Patient – a Rare Coincidence

Email alerts

ASH Publications

American Society of Hematology

Real-World Evidence of the Use of Carfilzomib Among Multiple Myeloma Patients with at Least One Prior Therapy across 10 European Countries and Israel

Real-World Evidence of the Use of Approved Carfilzomib Regimens in Patients Previously Exposed or Refractory to Lenalidomide: Updated Results from a Prospective Observational Study

Ixazomib, Thalidomide and Dexamethasone (IxaThalDex) in Relapsed/Refractory Multiple Myeloma (RRMM): An Interim Analysis of a Phase II Trial

Treatment with Bendamustine-Bortezomib-Dexamethasone (BBD) in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated

Significant Activity of Lenalidomide-Dexamethasone in Multiple Myeloma (MM) Patients with Light Chain Induced Acute Renal Failure (LC-ARF)

BCR-ABL Positive Chronic Myeloid Leukaemia (CML) with Del 11q22 and JAK 2 V617F Positive Chronic Myelomonocytic Leukaemia (CMML) in One Patient – a Rare Coincidence

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only